-
Ukraine denies Moscow claim of seizing strategic stronghold
-
Jefferson-Wooden holds off Richardson for Eugene 100m win
-
Dinusha shines for Sri Lanka on second day of West Indies Test
-
Stopping Haaland no mystery for Brazil, says Ancelotti
-
Julian Quinones, Mexico's not-so-secret World Cup weapon
-
Coach says Morocco 'no longer a surprise' after reaching World Cup quarters
-
Erasmus celebrates equalling record with win for weakened Springboks
-
Tuipulotu guides Scotland past Argentina with record score
-
'I'm going with him': families fear for bodies of Venezuela's quake dead
-
'Proud' Marsch says Canada better side in World Cup exit
-
Venezuela quake death toll rises to nearly 3,000
-
Norway must handle occasion against Brazil, says Solbakken
-
England unhappy with Rita Ora show before T20 World Cup final
-
Bethell upstages 'unbelievable' Sooryavanshi as England beat India
-
Morocco end Canada World Cup dream to reach quarters as France face Philly heat
-
'No point in racing' says frustrated Verstappen after British GP qualifying
-
Ruthless Morocco break Canadian hearts to reach World Cup quarters
-
Tour de France yellow gives Vingegaard crash closure
-
An 'angel' in darkness after Venezuela's deadly quakes
-
Smiling Antonelli proves all-round quality with pole at British GP
-
US turns 250 with Trump center stage
-
Vingegaard takes Tour de France lead with 'perfect start'
-
South Africa beat 13-man England in Nations Championship
-
Osaka eyes Sabalenka revenge in Wimbledon last 16
-
Vingegaard takes Tour de France lead as Visma win opening stage
-
Bethell upstages Sooryavanshi as England beat India in 2nd T20
-
Swiatek doesn't care about results after Wimbledon exit
-
Antonelli outpaces Ferraris to claim pole for British Grand Prix
-
England bid to emulate Lionesses and Red Roses in T20 World Cup final
-
Tens of thousands rally in France against sexual violence
-
French Open champ Zverev into Wimbledon last 16
-
Antonelli takes pole position for British Grand Prix
-
Teenage star Sooryavanshi out for 14 on India debut
-
'World Cup starts now' as Spain, Portugal clash in last 16
-
Splish-splash! Parisians and tourists soak in the Seine
-
A 'garden inside the Garden': More details of Swift-Kelce wedding emerge
-
Swiatek dumped out of Wimbledon by Eala, Serena withdraws from doubles
-
Serena Williams pulls out of Wimbledon doubles with knee injury
-
Swiatek's Wimbledon title defence ended by Philippines' Eala
-
Former champ Rybakina crashes out at Wimbledon
-
US celebrates 250th birthday as Trump warns of enemy within
-
Mass protests in Germany fail to stop far-right AfD congress
-
Farrell hails Ireland character in Wallabies win but says work to do
-
Ireland pip Australia 33-31 in Nations Championship nailbiter
-
Ireland edge Australia 33-31 in Nations Championship nailbiter
-
Antonelli edges Hamilton in sprint to extend title lead
-
Mali hit by new wave of coordinated rebel attacks
-
Rennie 'relief' as All Blacks tenure begins with narrow win over France
-
Hosts Canada, Mexico and USA thrive in their World Cup
-
Europe's baked rice bowl seeks escape from drought
Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology
LAS VEGAS, NEVADA / ACCESS Newswire / May 6, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the U.S. Food and Drug Administration (FDA) has scheduled its pre-submission meeting with Ainnova's executives and its CRO, Fortrea, for July 7, 2025, to discuss a range of items related to the Company's planned clinical trial of its Vision AI platform in the early detection of diabetic retinopathy.
Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We are forever grateful for the opportunity to meet with the U.S. FDA to discuss our planned clinical trial. These meetings will give us the direction that we'll need for success and to support our FDA 510(k) submission to obtain clearance from the FDA to market our technology in the U.S."
"We will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve our protocol for the planned clinical trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable."
AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
[email protected]
SOURCE: Avant Technologies
View the original press release on ACCESS Newswire
Th.Gonzalez--AT